(CIX: WRAL30)  1,127.58  up arrow+21.3  (1.93 %)  Updated: 12:53 PM EST, Jan 28 2015
(NQ: Apple)  117.55  up arrow+8.41  (7.71 %)  Updated: 12:54 PM EST, Jan 28 2015
(NY: QUINTILES)  62.14  up arrow+0.24  (0.39 %)  Updated: 12:53 PM EST, Jan 28 2015
(OP: BASF SE)  89.45  up arrow+1.67  (1.9 %)  Updated: 12:51 PM EST, Jan 28 2015
(NQ: BioCryst)  10.79  down arrow-0.27  (-2.44 %)  Updated: 12:53 PM EST, Jan 28 2015
(NQ: BioDelivery)  13.77  down arrow-0.12  (-0.86 %)  Updated: 12:52 PM EST, Jan 28 2015
(NQ: CEMP)  27.44  up arrow+1.13  (4.29 %)  Updated: 12:54 PM EST, Jan 28 2015
(NQ: Cisco Systems)  27.36  up arrow+0.46  (1.71 %)  Updated: 12:54 PM EST, Jan 28 2015
(NQ: Cree)  36.34  down arrow-0.52  (-1.41 %)  Updated: 12:53 PM EST, Jan 28 2015
(NQ: DARA)  0.82  down arrow-0.01  (-1.2 %)  Updated: 12:47 PM EST, Jan 28 2015
(NY: EMC CORPORATION)  27.28  down arrow-0.13  (-0.47 %)  Updated: 12:54 PM EST, Jan 28 2015
(NQ: Extreme Networks)  2.80  up arrow+0.1  (3.7 %)  Updated: 12:53 PM EST, Jan 28 2015
(NQ: FB)  77.42  up arrow+1.64  (2.16 %)  Updated: 12:54 PM EST, Jan 28 2015
(NY: GLAXOSMITHKLINE)  45.44  up arrow+0.28  (0.62 %)  Updated: 12:54 PM EST, Jan 28 2015
(NQ: GOOG)  518.49  down arrow-0.14  (-0.03 %)  Updated: 12:53 PM EST, Jan 28 2015
(NY: IBM)  153.62  down arrow-0.05  (-0.03 %)  Updated: 12:54 PM EST, Jan 28 2015
(NY: LH)  116.51  up arrow+0.22  (0.19 %)  Updated: 12:53 PM EST, Jan 28 2015
(OP: Lenovo Group)  26.68  down arrow-0.35  (-1.29 %)  Updated: 12:36 PM EST, Jan 28 2015
(NY: MRK)  62.31  down arrow-0.25  (-0.39 %)  Updated: 12:54 PM EST, Jan 28 2015
(NQ: Microsoft Corp)  42.27  down arrow-0.39  (-0.91 %)  Updated: 12:54 PM EST, Jan 28 2015
(NQ: NTAP)  38.38  up arrow+0.31  (0.81 %)  Updated: 12:54 PM EST, Jan 28 2015
(NY: NOVARTIS AG)  98.40  down arrow-0.53  (-0.54 %)  Updated: 12:53 PM EST, Jan 28 2015
(OP: Novozymes A/S)  45.82  down arrow-0.31  (-0.66 %)  Updated: 12:25 PM EST, Jan 28 2015
(NY: PFIZER)  32.32  down arrow-0.29  (-0.87 %)  Updated: 12:54 PM EST, Jan 28 2015
(NQ: Pozen)  7.00  down arrow-0.15  (-2.1 %)  Updated: 12:53 PM EST, Jan 28 2015
(NY: RED HAT)  65.47  up arrow+0.39  (0.6 %)  Updated: 12:54 PM EST, Jan 28 2015
(NQ: BBRY)  10.37  down arrow-0.19  (-1.8 %)  Updated: 12:53 PM EST, Jan 28 2015
(NQ: Salix)  127.95  up arrow+1.65  (1.31 %)  Updated: 12:54 PM EST, Jan 28 2015
(NQ: SQI)  13.87  down arrow-0.29  (-2.05 %)  Updated: 12:53 PM EST, Jan 28 2015

Posts tagged “Salix”

August 8, 2013

Premium Lock Salix CEO Logan talks about M&A strategy

Salix Even though Salix Pharmaceuticals has diversified its portfolio of gastrointestinal drug treatments, CEO Carolyn Logan says Salix is always looking for deals. Read what she has to say about Salix's acquisition strategy.

Updated June 11, 2013

Premium Lock Salix constipation drug Relistor to go before FDA advisory panel

Salix Salix Pharmaceuticals' (NASDAQ:SLXP) constipation drug Relistor, which failed to win regulatory approval last year, will be up for review by a FDA advisory committee.

May 22, 2013

Premium Lock Salix rectal inflammation drug shows positive clinical trial results

Salix Salix Pharmaceuticals' topical foam to treat rectal inflammation could be filed for approval with the Food and Drug Administration by the end of September.

Updated May 10, 2013

Premium Lock Prescription growth lifts Salix's 1Q sales

Salix First quarter sales of Salix Pharmaceuticals' top drug, Xifaxan, increased 18 percent year over year. Read more about the company's performance.

Updated May 10, 2013

Premium Lock FDA makes Salix wait on constipation drug; company says no new trials needed

Salix The FDA said it needed more data to approve expanded use of Salix Pharmaceutical's constipation drug Relistor. Read why Salix thinks it has enough information.

Updated March 6, 2013

Premium Lock Salix CEO gears for federal probe that could go on for 'quite some time'

Salix Carolyn Logan, chief executive officer at Raleigh-based Salix pharmaceuticals, and the company are gearing up for what could be a lengthy federal investigation into its marketing practices.

Updated February 15, 2013

Premium Lock Feds subpoena Salix, ask about drug promotion practices

Salix Federal prosecutors have questions about how Salix Pharmaceuticals (NASDAQ:SLXP) sells and promotes its drugs, including its top-selling product Xifaxan.

January 3, 2013

Premium Lock Drug approval sends Salix shares up nearly 5%

Salix Shares in Salix Pharmaceuticals rose nearly 5 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.

January 2, 2013

Premium Lock FDA approves new Salix drug to treat AIDS-related diarrhea

Salix Shares in Salix Pharmaceuticals rose more than 3 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.

November 8, 2012

Premium Lock Earnings: Salix; PowerSecure; Pozen; BioCryst

Bulldog Inside the Bulldog Blog: Revenues up at Salix; record revenues for PowerSecure; Pozen cuts losses; net loss declines at Biocryst;

Updated October 23, 2012

Premium Lock Raleigh drug firm Salix sponsors documentary on liver disease

Salix Pharmaceuticals and the American Liver Foundation back a new documentary about hepatic encephalopathy, or HE, which was directed by Academy Award winner Cynthia Wade.

Salix backs "HE" documentary Salix backs "HE" documentary

September 5, 2012

Premium Lock FDA again delays Salix gastrointestinal drug

Salix The FDA has again delayed an approval decision for a new diarrhea drug from Salix Pharmaceuticals.

August 9, 2012

Premium Lock Salix pays $10M upfront for possible treatment of Crohn's Disease

Salix The Raleigh-based pharmaceutical firm licenses rights to an extended release version of the drug Rifaximin that targets gastrointestinal and respiratory ailments.

August 9, 2012

Premium Lock Earnings: Salix, Cempra, Targacept, Cornerstone

Earnings    Four North Carolina-based life science firms report an overall mixed bag of results, but Raleigh-based Salix reports huge jump in sales.

Updated July 31, 2012

Premium Lock Salix delays big hiring plans after FDA rejects drug

Salix Salix will no longer add an additional 160 primary-care sales representatives later this year and plans to update its 2012 earnings forecast when it releases second-quarter results on Aug. 8.

July 30, 2012

Premium Lock In the news: Quintiles, Salix, Furiex, AAD

Bulldog Inside the Bulldog Blog: Quintiles lands drug promotion deal; Salix seeks FDA meeting about drug response; Furiex resubmits diabetes drug; Advanced Animal Diagnostics adds two execs.

May 8, 2012

Premium Lock Salix revenue rises 62% in first quarter, beats Street

Salix Salix Pharmaceuticals announced on Monday a 62 percent increase in its first quarter revenue for 2012 with total product revenue at $171.1 million thanks in part to the company's leading drug Xifaxan.

Tags: Salix
May 1, 2012

Premium Lock FDA delays decision on Salix drug to treat HIV-related diarrhea

HIV research Salix had been scheduled for a June 5 decision date on its experimental diarrhea treatment crofelemer. But the Raleigh company says FDA regulators need more time to review the submission.

April 26, 2012

Premium Lock FDA oushes back review for Salix constipation treatment

Salix An approval decision was expected on April 27. But the U.S. Food and Drug Administration has notified the Raleigh-based company that it needs more time. The new target date to issue an approval decision is July 27.

March 13, 2012

Premium Lock Raleigh-based Salix Pharmaceuticals to raise $600M

Salix Salix says it will repurchase outstanding convertible senior notes that are due in 2028. The company also plans to repurchase up to $75 million of its outstanding common stock and will also use proceeds for corporate purposes.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith